MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
$5,254,514
Free Cash flow
-$18,047,227
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of warran...
Proceeds from sale of investment...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Change in fair value of common s...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,012,458
-19,682,798
3,764,880
-88,710,781
Depreciation
322,034
316,844
340,197
350,198
Amortization of operating lease right-of-use assets
443,852
428,620
413,857
399,458
Change in fair value of common stock warrant liabilities
-13,868,616
-4,137,703
-21,174,099
20,680,868
Non-cash stock-based compensation
768,437
698,744
764,561
757,086
Non-cash interest on senior convertible notes
-
-
0
0
Amortization of discounts on investments
8,032
10,062
53,266
-63,870
Loss on sales of short-term investments
-573,444
-284,690
-28
-182,904
Net gain on disposal of fixed assets
-
-
0
0
Loss (gain) on equity investment in affiliated entity
0
-2,103,688
-392,042
881,886
Net unrealized gain on available-for-sale equity securities
94,221
79,077
9,999
1,104,782
Accounts receivable from affiliated entity
-
-
-
138,278
Prepaid expenses and other current assets, including from affiliated entity
1,480,884
-852,534
-1,986,708
-908,843
Other assets
-95,406
-
-1
0
Accounts payable and accrued expenses, including due to affiliated entity
2,385,747
-1,860,676
-4,575,150
-350,130
Accrued clinical trial expenses
-478,870
166,651
-305,290
-555,014
Operating lease right-of-use assets and liabilities, net
-693,066
-672,771
-652,401
-638,001
Grant funding liability, including from affiliated entity
-
-
-
42,152
Net cash used in operating activities
-18,047,227
-21,591,316
-19,370,549
-21,573,495
Purchases of investments
-994,539
2,976,627
0
0
Proceeds from sale of investments
4,152,141
4,612,484
-4,930,745
8,935,184
Proceeds from maturity of investments
1,000,000
1,000,000
5,000,000
-
Purchases of capital assets
0
0
127,444
67,951
Proceeds from sale of capital assets
-
-
0
-
Net cash provided by investing activities
6,146,680
2,635,857
-58,189
8,867,233
Repayment of convertible senior notes
-
-
0
0
Proceeds from issuance of warrants, net of issuance costs-Pre Funded Warrants
-
-
0
0
Proceeds from issuance of common stock, net of issuance costs
3,247,068
1,084,027
26,621,316
7,185,128
Proceeds from issuance of warrants, net of issuance costs-Warrant
-
-
0
16,986,830
Proceeds from warrant exercises
-
-
512,498
752,134
Proceeds from stock option exercises
-
-
823
0
Proceeds from issuance of warrants, net of issuance costs
13,963,956
-
-
-
Taxes paid related to net share settlement of equity awards
-55,963
-130,237
0
-1,787
Net cash provided by financing activities
17,155,061
953,790
27,134,637
24,922,305
Effect of exchange rate changes on cash and cash equivalents
-
-
0
0
Decrease in cash and cash equivalents
5,254,514
-18,001,669
7,705,899
12,216,043
Cash and cash equivalents, beginning of period
26,271,650
44,273,319
36,567,420
65,813,297
Cash and cash equivalents, end of period
31,526,164
26,271,650
44,273,319
36,567,420
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
INO Cash Flow Sankey Diagram
Sankey diagram visualizing INO cash flow for the period
Proceeds from issuance of
warrants, net of issuance...
$13,963,956
Proceeds from issuance of
common stock, net of...
$3,247,068
(194.61%↑ Y/Y)
Proceeds from sale of
investments
$4,152,141
(-59.56%↓ Y/Y)
Proceeds from maturity of
investments
$1,000,000
Purchases of investments
-$994,539
(-120.11%↓ Y/Y)
Net cash provided by
financing activities
$17,155,061
(1627.33%↑ Y/Y)
Net cash provided by
investing activities
$6,146,680
(17.52%↑ Y/Y)
Canceled cashflow
$55,963
Decrease in cash and cash
equivalents
$5,254,514
(112.67%↑ Y/Y)
Canceled cashflow
$18,047,227
Taxes paid related to
net share...
-$55,963
(48.66%↑ Y/Y)
Accounts payable and
accrued expenses,...
$2,385,747
(259.28%↑ Y/Y)
Non-cash stock-based
compensation
$768,437
(-65.60%↓ Y/Y)
Loss on sales of
short-term investments
-$573,444
(19.00%↑ Y/Y)
Amortization of operating
lease right-of-use...
$443,852
(-41.41%↓ Y/Y)
Depreciation
$322,034
(-55.74%↓ Y/Y)
Other assets
-$95,406
(-390.68%↓ Y/Y)
Net cash used in
operating activities
-$18,047,227
(62.15%↑ Y/Y)
Canceled cashflow
$4,588,920
Change in fair value of
common stock warrant...
-$13,868,616
Net loss
-$6,012,458
Prepaid expenses and
other current assets,...
$1,480,884
(-17.26%↓ Y/Y)
Operating lease
right-of-use assets and...
-$693,066
(42.58%↑ Y/Y)
Accrued clinical trial
expenses
-$478,870
(6.26%↑ Y/Y)
Net unrealized gain
on...
$94,221
Amortization of discounts on
investments
$8,032
(-38.23%↓ Y/Y)
Buy us a coffee
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)